MAPT and dementia: A recent successful phase II clinical trial with the Aβ antibody donanemab, however, took an innovative approach by selecting Aβ‐positive individuals MCI/mild dementia with intermediate levels of tau pathology based on a PET scan (Mintun et al, 2021).